Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular Dystrophy
January 06, 2016 17:46 ET | FibroGen, Inc.
SAN FRANCISCO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”) announced today enrollment of the first two patients in an open-label, multicenter Phase 2 clinical...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Third Quarter 2015 Financial Results
November 12, 2015 16:02 ET | FibroGen, Inc.
SAN FRANCISCO, Nov. 12, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the quarter ended...
Fibrogen_US_Primary_logo_RGB_M01.jpg
Phase 2 Data for Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Show Anemia Correction in Incident Dialysis Chronic Kidney Disease Patients Regardless of Iron Repletion Status, Iron Supplementation Regimen, or Dialysis Modality
October 22, 2015 19:14 ET | FibroGen, Inc.
SAN FRANCISCO, Oct. 22, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, along with its partner, AstraZeneca (NYSE:AZN), today...